Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: the study protocol of a randomised pilot trial

A Bogosian, C S Hurt, D Vasconcelos E Sa, J V Hindle, L McCracken, P Cubi-Molla, A Bogosian, C S Hurt, D Vasconcelos E Sa, J V Hindle, L McCracken, P Cubi-Molla

Abstract

Background: Psychological difficulties, especially depression and anxiety, are the most prevalent non-motor symptoms in Parkinson's disease. Pharmacological treatments for these conditions appear relatively ineffective in Parkinson's disease. Mindfulness courses are increasingly popular and recognised as effective for managing emotional states, and there is growing evidence for the effectiveness of mindfulness courses for people with long-term medical conditions. With this exploratory pilot trial, we want to assess the feasibility of the procedures and processes, including recruitment, most appropriate outcome measure(s), acceptability of type and number of measures, potential nocebo effects, and potential effectiveness and cost-effectiveness of a specially adapted distance-delivered mindfulness-based intervention in people affected by Parkinson's disease.

Methods/design: This is a pilot two-arm randomised parallel group controlled trial. Sixty participants who meet eligibility criteria will be randomly assigned either to an 8-week mindfulness-based intervention group or a wait-list control group. The mindfulness intervention will include 1-h weekly sessions delivered by a health psychologist trained to facilitate mindfulness courses. Participants in both groups will complete standardised questionnaires assessing anxiety, depression, pain, insomnia, fatigue, and daily activities at four time points (baseline, 4, 8, and 20 weeks). The analysis will also consider potential mechanisms of change, such as acceptance, self-compassion, and tolerance of uncertainty, as well as health economic outcomes. Participants' experiences of the mindfulness interventions will be explored via in-depth interviews.

Discussion: A mindfulness-based intervention for people with Parkinson's delivered remotely, through Skype group videoconferences, may represent a viable, more accessible, intervention for people with mobility limitations and people who live in rural areas. The trial will provide important information about the feasibility, potential efficacy and cost-effectiveness, and acceptability of the intervention as well as mechanisms of psychosocial adjustment. The results of this pilot trial will help us design a phase III trial to assess efficacy of an online mindfulness-based intervention in Parkinson's disease and evaluate significance.

Trial registration: ClinicalTrials.gov, NCT02683330.

Keywords: Anxiety; Depression; Mindfulness; Parkinson’s disease; Randomised controlled trial.

Figures

Fig. 1
Fig. 1
CONSORT flowchart of trial design

References

    1. Hinnell C, et al. Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson’s disease? Mov Disord. 2012;27(2):236–241. doi: 10.1002/mds.23961.
    1. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–45. doi: 10.1016/S1474-4422(06)70373-8.
    1. Burn DJ. Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov Disord. 2002;17(3):445–54. doi: 10.1002/mds.10114.
    1. Brown RG, et al. Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2011;82(7):803–809. doi: 10.1136/jnnp.2010.213652.
    1. Weintraub D, et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov Disord. 2005;20(9):1161–9. doi: 10.1002/mds.20555.
    1. Frisina PG, et al. Depression in Parkinson’s disease: health risks, etiology, and treatment options. Neuropsychiatr Dis Treat. 2008;4(1):81–91.
    1. Connolly BS, Fox SH. Drug treatments for the neuropsychiatric complications of Parkinson’s disease. Expert Rev Neurother. 2012;12(12):1439–49. doi: 10.1586/ern.12.142.
    1. Weintraub D, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–55. doi: 10.1212/WNL.0b013e3181ebdd79.
    1. Hanagasi HA, Emre M. Treatment of behavioural symptoms and dementia in Parkinson’s disease. Fundam Clin Pharmacol. 2005;19(2):133–46. doi: 10.1111/j.1472-8206.2005.00317.x.
    1. Dobkin RD, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168(10):1066–74. doi: 10.1176/appi.ajp.2011.10111669.
    1. Cole K, Vaughan FL. The feasibility of using cognitive behaviour therapy for depression associated with Parkinson’s disease: a literature review. Parkinsonism Relat Disord. 2005;11(5):269–76. doi: 10.1016/j.parkreldis.2005.03.002.
    1. Feeney F, Egan S, Gasson N. Treatment of depression and anxiety in Parkinson’s disease: a pilot study using group cognitive behavioural therapy. Clin Psychol. 2005;9(1):31–38. doi: 10.1080/13284200500048240.
    1. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression: a new approach to preventing relapse. New York: The Guilford Press; 2002.
    1. Grossman P, et al. Mindfulness-based stress reduction and health benefits. A meta-analysis. J Psychosom Res. 2004;57(1):35–43. doi: 10.1016/S0022-3999(03)00573-7.
    1. Pickut B, et al. Mindfulness training among individuals with Parkinson’s disease: neurobehavioral effects. Parkinson’s Disease. 2015;2015:816404.
    1. Dissanayaka NWN, et al. Mindfulness for motor and nonmotor dysfunctions in Parkinson’s disease. Parkinson’s Disease. 2016;2016:13.
    1. Cash TV, et al. Pilot study of a mindfulness-based group intervention for individuals with Parkinson’s disease and their caregivers. Mindfulness. 2016;7(2):361–71.
    1. Fitzpatrick L, Simpson J, Smith A. A qualitative analysis of mindfulness-based cognitive therapy (MBCT) in Parkinson’s disease. Psychol Psychother. 2010;83(Pt 2):179–92. doi: 10.1348/147608309X471514.
    1. Pickut BA, et al. Mindfulness based intervention in Parkinson’s disease leads to structural brain changes on MRI: a randomized controlled longitudinal trial. Clin Neurol Neurosurg. 2013;115(12):2419–25. doi: 10.1016/j.clineuro.2013.10.002.
    1. Ljotsson B, et al. Long-term follow-up of internet-delivered exposure and mindfulness based treatment for irritable bowel syndrome. Behav Res Ther. 2011;49(1):58–61. doi: 10.1016/j.brat.2010.10.006.
    1. Hawkes AL, et al. CanPrevent: a telephone-delivered intervention to reduce multiple behavioural risk factors for colorectal cancer. BMC Cancer. 2012;12(1):560. doi: 10.1186/1471-2407-12-560.
    1. Thompson NJ, et al. Distance delivery of mindfulness-based cognitive therapy for depression: project UPLIFT. Epilepsy Behav. 2010;19(3):247–54. doi: 10.1016/j.yebeh.2010.07.031.
    1. Browne RH. On the use of a pilot sample for sample size determination. Stat Med. 1995;14(17):1933–1940. doi: 10.1002/sim.4780141709.
    1. Hughes AJ. What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. 1992. Neurology. 2001;57(10 suppl 3):S34–8.
    1. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–752. doi: 10.1136/jnnp.51.6.745.
    1. Brandt J, et al. Hereditary influences on cognitive functioning in older men: a study of 4000 twin pairs. Arch Neurol. 1993;50(6):599–603. doi: 10.1001/archneur.1993.00540060039014.
    1. Carmody J, Baer RA. How long does a mindfulness-based stress reduction program need to be? A review of class contact hours and effect sizes for psychological distress. J Clin Psychol. 2009;65(6):627–638. doi: 10.1002/jclp.20555.
    1. Tavee J, et al. Effects of meditation on pain and quality of life in multiple sclerosis and peripheral neuropathy: a pilot study. Int J MS Care. 2011;13(4):163–8. doi: 10.7224/1537-2073-13.4.163.
    1. Macniven J, Gaskill A. Psychological services for people with Parkinson’s disease. P.P. Board, editor. Leicester: The British Psychological Society; 2009.
    1. Thabane L, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10(1):1. doi: 10.1186/1471-2288-10-1.
    1. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatric Scandinavia. 1983;67:361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale—a review of validation data and clinical results. J Psychosom Res. 1997;42(1):17–41. doi: 10.1016/S0022-3999(96)00216-4.
    1. Price DD, et al. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain. 1994;56(2):217–26. doi: 10.1016/0304-3959(94)90097-3.
    1. Krupp LB, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3. doi: 10.1001/archneur.1989.00520460115022.
    1. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2(4):297-07
    1. Hobson JP, Edwards NI, Meara RJ. The Parkinson’s Disease Activities of Daily Living Scale: a new simple and brief subjective measure of disability in Parkinson’s disease. Clin Rehabil. 2001;15(3):241–246. doi: 10.1191/026921501666767060.
    1. Raes F, et al. Construction and factorial validation of a short form of the Self-Compassion Scale. Clin Psychol Psychother. 2011;18(3):250–5. doi: 10.1002/cpp.702.
    1. Fresco DM, et al. Initial psychometric properties of the experiences questionnaire: validation of a self-report measure of decentering. Behav Ther. 2007;38(3):234–46. doi: 10.1016/j.beth.2006.08.003.
    1. Hayes SC, et al. Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther. 2006;44(1):1–25.
    1. Bond FW, et al. Preliminary psychometric properties of the Acceptance and Action Questionnaire—II: a revised measure of psychological flexibility and acceptance. Behav Ther. 2011;42:676–688. doi: 10.1016/j.beth.2011.03.007.
    1. Cardaciotto L, et al. The assessment of present-moment awareness and acceptance: The Philadelphia Mindfulness Scale. Assessment. 2008;15(2):204–223. doi: 10.1177/1073191107311467.
    1. Carleton RN, Norton MAPJ, Asmundson GJG. Fearing the unknown: a short version of the Intolerance of Uncertainty Scale. Journal of Anxiety Disorders. 2007;21(1):105–117. doi: 10.1016/j.janxdis.2006.03.014.
    1. Dolan P, Layard R, Metcalfe R. Measuring subjective well-being for public policy. London, UK: Office for National Statistics; 2011.
    1. Group TE. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208. doi: 10.1016/0168-8510(90)90421-9.
    1. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72. doi: 10.1016/0168-8510(96)00822-6.
    1. Al-Janabi H, Flynn TN, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21(1):167–176. doi: 10.1007/s11136-011-9927-2.
    1. Malley JN, et al. An assessment of the construct validity of the ASCOT measure of social care-related quality of life with older people. Health and Quality of Life Outcomes. 2012;10(1):1–14. doi: 10.1186/1477-7525-10-21.
    1. Boutron I, et al. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008;148(4):295–309. doi: 10.7326/0003-4819-148-4-200802190-00008.
    1. Patton M. Qualitative evaluation and research methods. Thousand Oaks, California: Sage Publications Ltd.; 1990.
    1. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi: 10.1191/1478088706qp063oa.
    1. Glaser B, Strauss SA. Discovery of grounded theory. Strategies for qualitative research. New York: Aldine de Gruyter; 1967.
    1. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG, editors. Analysing Qualitative Data. London: Routledge; 1994. p 173–194.
    1. Kabat-Zinn J. Full catastrophe living, revised edition: how to cope with stress, pain and illness using mindfulness meditation. London: Piatkus; 2013.
    1. Furukawa TA, et al. Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand. 2014;130(3):181–92. doi: 10.1111/acps.12275.
    1. Poole NA, Morgan JF. Validity and reliability of the Hospital Anxiety and Depression Scale in a hypertrophic cardiomyopathy clinic: the HADS in a cardiomyopathy population. Gen Hosp Psychiatry. 2006;28(1):55–8. doi: 10.1016/j.genhosppsych.2005.08.004.
    1. Johnston M, Pollard B, Hennessey P. Construct validation of the hospital anxiety and depression scale with clinical populations. J Psychosom Res. 2000;48(6):579–84. doi: 10.1016/S0022-3999(00)00102-1.
    1. Michopoulos I, et al. Hospital Anxiety and Depression Scale (HADS): validation in a Greek general hospital sample. Ann Gen Psychiatry. 2008;7:4. doi: 10.1186/1744-859X-7-4.
    1. Herrero MJ, et al. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. Gen Hosp Psychiatry. 2003;25(4):277–83. doi: 10.1016/S0163-8343(03)00043-4.
    1. Turner A, et al. Depression screening in stroke: a comparison of alternative measures with the structured diagnostic interview for the diagnostic and statistical manual of mental disorders, fourth edition (major depressive episode) as criterion standard. Stroke. 2012;43(4):1000–5. doi: 10.1161/STROKEAHA.111.643296.
    1. Cameron IM, Reid IC, Lawton K. PHQ-9: sensitivity to change over time. Br J Gen Pract. 2010;60(576):535–6. doi: 10.3399/bjgp10X514909.
    1. Bogosian A, et al. Potential treatment mechanisms in a mindfulness-based intervention for people with progressive multiple sclerosis. Br J Health Psychol. 2016;21(4):859–880. doi: 10.1111/bjhp.12201.
    1. A. Bogosian, P. Chadwick, S. Windgassen, S. Norton, P. McCrone, I. Mosweu, E. Silber, R. Moss-Morris, A. Bogosian, P. Chadwick, S. Windgassen, S. Norton, P. McCrone, I. Mosweu, E. Silber, R. Moss-Morris. Distress improves after mindfulness training for progressive MS: A pilot randomised trial. Multiple Sclerosis Journal. 2015;21(9):1184–94.
    1. Neff, K. D. The Role of Self-Compassion in Development: A Healthier Way to Relate to Oneself. Human Development. 2009;52(4):211–4.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다